EVALUATION OF ANTIANGIOGENIC THERAPY OF BREAST CANCER USING PARACEST MRI

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。根据美国癌症协会2004年的统计数据，乳腺癌仍然是美国女性癌症死亡的第二大原因。这突显了研究乳腺癌检测技术的必要性，以促进在疾病的早期阶段发现和治疗。具有高灵敏度和高特异度的检测技术也将降低目前乳腺肿块妇女的高阴性活检比率，并有助于定制个性化的治疗方案。用常规的、改变T1的小分子造影剂增强的乳腺磁共振成像(MRI)对乳腺癌的检测具有很高的敏感性，但对检测到的病变特征的特异度有限。传统的大分子造影剂有可能提供这种组织分化，但敏感性较低。人们不能同时使用这两种药剂，因为无法区分这两种药剂的效果。基于化学交换饱和转移(CEST)效应的新型顺磁性造影剂最近被提出应用于磁共振成像。这类新的对比剂亟需在体内进行评估，特别是因为这些造影剂的理论预测灵敏度高于传统的基于Gd的造影剂。由于与Gd-DTPA相比，Gd-DTPA的T1弛豫度非常低，其给药不会影响随后对同一对象进行的Gd-DTPA研究。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Breast cancer continues to be the second leading cause of cancer deaths in American women according to American Cancer Society statistics for 2004. This highlights the need for research in breast cancer detection techniques to facilitate detection and treatment at an early stage in the disease. A detection technique with high sensitivity and specificity would also decrease the current high rate of negative biopsies of women with breast masses and help tailor individualized therapeutic options. Magnetic resonance imaging (MRI) of the breast enhanced with conventional, T1 altering, small molecular contrast agents have a high sensitivity for breast cancer detection but a limited specificity for characterization of the detected lesions. Conventional macromolecular contrast agents have the potential to provide this tissue differentiation but the sensitivity is low. One cannot use these two types of agents together as it would be impossible to distinguish between effects of the two. A novel class of paramagnetic contrast agents based on the chemical exchange saturation transfer (CEST) effect has been recently proposed for MRI applications. This new class of ¿PARACEST¿ contrast agents needs to be urgently evaluated in vivo especially since the theoretically predicted sensitivity of these agents is higher than conventional Gd-based agents. Due to its very low T1 relaxivity compared to Gd-DTPA, its administration will not affect a Gd-DTPA study performed on the same subject subsequently.